Trial · NCT06055465
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pathological complete response (pCR) rate in the intention-to-treat population | 2 years | |
| Secondary | Resection rate after neoadjuvant SG and pembrolizumab combination: proportion of patients who undergo surgery with curative intent | 2 years | |
| Secondary | pCR rates in patients who undergo surgery | 2 years | |
| Secondary | Major pathological response (MPR) rate in the ITT population and in patients who undergo surgery: MPR is defined as less than 10% viable tumor cells in resected primary tumour specimen | 2 years | |
| Secondary | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 while on neoadjuvant SG and pembrolizumab combination | 2 years | |
| Secondary | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 while on adjuvant pembrolizumab | 2 years | |
| Secondary | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 first 30 days after surgery | 2 years | |
| Secondary | Objective response rate (ORR): rate of partial and complete response on CT scans according to RECIST criteria ver 1.1 | 2 years | |
| Secondary | Overall Survival | 2 years | |
| Secondary | 12 month and 24 month event-free survival (EFS) rate | 2 years | |
| Secondary | Patient reported quality of life (QOL), as measured by EQ-5D-3L during study treatment. | 2 years | For the descriptive system of EQ-5D-3L, three levels of problems are described in each dimension. For the Visual Analogue Scale (VAS), the overall health assessment of the respondent is captured, ranging from 0 (worst health imaginable) to 100 (best health imaginable) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06055465/registered